DNTH vs KRYS: which is the better buy in 2026?
On Alexandria's Compass, Dianthus Therapeutics, Inc. has the edge with a 90/100 score versus 52/100 for KRYS. Here is how they stack up, factor by factor.
Dianthus Therapeutics, Inc.
NASDAQ:DNTH
Claseprubart is shaping up as the next-generation complement franchise, with gMG data due to reset how the Street values C1s inhibition.
Full DNTH analysisKrystal Biotech, Inc.
NASDAQ:KRYS
VYJUVEK is the proof of concept that gene therapy works as a topical, repeatable product. The pipeline is the real prize.
Full KRYS analysisFactor by factor
Get head-to-heads like this, free
Join the Alexandria e-letter for Compass verdicts, earnings intelligence, and the contrarian calls the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is DNTH or KRYS the better buy in 2026?
By Compass Score, Dianthus Therapeutics, Inc. (NASDAQ:DNTH) edges it at 90/100 versus 52/100 for KRYS. Both scores update weekly and reflect a contrarian, forward-looking read, not a recommendation.
How does Alexandria compare DNTH and KRYS?
Each company is scored 1-100 on eight factors: revenue growth, profitability, valuation, momentum, theme purity, moat, catalysts, and market position. The Compass Score is the composite, and the comparison below shows where each name wins factor by factor.
Compass Scores are proprietary editorial research from publicly available data, not investment advice or a recommendation regarding any security. Rankings update weekly.